Skip Navigation



European Heart Journal Advance Access published online on July 6, 2006
European Heart Journal, doi:10.1093/eurheartj/ehl135
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
27/15/1841    most recent
ehl135v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Yin, Y.
Right arrow Articles by Dong, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yin, Y.
Right arrow Articles by Dong, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

European Heart Journal © The European Society of Cardiology 2006; all rights reserved
Received January 3, 2006
Revised May 15, 2006
Accepted June 15, 2006

Clinical research

Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation

Yuehui Yin 1 *, Darshan Dalal 2, Zengchang Liu 1, Jinjin Wu 1, Dong Liu 1, Xianbin Lan 1, Yin Dai 1, Li Su 1, Zhiyu Ling 1, Qiang She 1, Kailiang Luo 1, Kamsang Woo 3, and Jun Dong 4

1 Department of Cardiology, the Second Affiliated Hospital of Chongqing University of Medical Sciences, Chongqing 400010, China
2 Department of Medicine/Cardiology, The Johns Hopkins University School of Medicine, The Johns Hopkins Hospital/Carnegie 592, 600 N. Wolfe Street, Baltimore, MD 21287, USA
3 Department of Medicine and Therapeutics, The Chinese University of Hongkong, Hongkong, China
4 Department of Cardiology, the Second Affiliated Hospital of Chongqing University of Medical Sciences, Chongqing 400010, China; Department of Medicine/Cardiology, The Johns Hopkins University School of Medicine, The Johns Hopkins Hospital/Carnegie 592, 600 N. Wolfe Street, Baltimore, MD 21287, USA

* To whom correspondence should be addressed.
Yuehui Yin, E-mail: yinyuehui63{at}yahoo.com.cn


  Abstract

Aims The purpose of this trial was to compare the long-term efficacy of low-dose amiodarone with losartan and perindopril (both combined with low-dose amiodarone) for the prevention of atrial fibrillation (AF) recurrence in patients with lone paroxysmal AF.

Methods and results One-hundred and seventy-seven patients with lone paroxysmal AF were randomly assigned to three treatment groups: group 1 received low-dose amiodarone alone, group 2 received low-dose amiodarone plus losartan, and group 3 received low-dose amiodarone plus perindopril. Left atrial diameter was measured with transthoracic echocardiogram at baseline and 6, 12, 18, and 24 months after randomization. The primary endpoint was the incidence of AF documented by 12-lead ECG or Holter after 14 days and within 24 months after randomization. The primary endpoint was reached in 24 patients (41%) in group 1, 11 (19%) in group 2, and 14 (24%) in group 3 (P = 0.02). The Kaplan-Meier survival analysis demonstrated a significant reduction in AF recurrence in group 2 (P = 0.006, log-rank test) as well as in group 3 (P = 0.04, log-rank test) when compared with group 1. No difference in the AF recurrence-free survival was found between group 2 and group 3. After 24 months follow-up, the left atrial diameter in group 2 and group 3 was significantly smaller than that in group 1 (36 ± 2.3 and 35 ± 2.4 vs. 38 ± 2.4 mm, P < 0.001 for both comparisons).

Conclusion The results of this study suggest that the combination of perindopril or losartan with low-dose amiodarone is more effective than low-dose amiodarone alone for the prevention of AF recurrence in patients with lone paroxysmal AF. Adding losartan or perindopril to amiodarone can inhibit left atrial enlargement in this group of patients.

Keywords: Atrial fibrillation; Amiodarone; Losartan; Perindopril.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 EuropaceHome page
S. K. Kim, H.-N. Pak, J. H. Park, K. J. Ko, J. S. Lee, J. I. Choi, D. H. Choi, and Y.-H. Kim
Clinical and serological predictors for the recurrence of atrial fibrillation after electrical cardioversion
Europace, October 26, 2009; (2009) eup321v1.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
S Zhang
Atrial fibrillation in mainland China: epidemiology and current management
Heart, July 1, 2009; 95(13): 1052 - 1055.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
B. Ozben, M. Sumerkan, A. M. Tanrikulu, N. Papila-Topal, A. S. Fak, and A. Toprak
Perindopril decreases P wave dispersion in patients with stage 1 hypertension
Journal of Renin-Angiotensin-Aldosterone System, June 1, 2009; 10(2): 85 - 90.
[Abstract] [PDF]

Home page
 NEJMHome page
The GISSI-AF Investigators
Valsartan for Prevention of Recurrent Atrial Fibrillation
N. Engl. J. Med., April 16, 2009; 360(16): 1606 - 1617.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. M. Gillis
Angiotensin-Receptor Blockers for Prevention of Atrial Fibrillation -- A Matter of Timing or Target?
N. Engl. J. Med., April 16, 2009; 360(16): 1669 - 1671.
[Full Text] [PDF]

Home page
 JAMAHome page
S. Ahmed, H. J. G. M. Crijns, and I. C. Van Gelder
Treatment With Amiodarone to Prevent Atrial Fibrillation--Reply
JAMA, March 11, 2009; 301(10): 1020 - 1020.
[Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
P. Dorian and B. N. Singh
Upstream therapies to prevent atrial fibrillation
Eur. Heart J. Suppl., September 1, 2008; 10(suppl_H): H11 - H31.
[Abstract] [Full Text] [PDF]

Home page
 Ther Adv Cardiovasc DisHome page
J. L. Serra and M. Bendersky
Review: Atrial fibrillation and renin-angiotensin system
Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 215 - 223.
[Abstract] [PDF]

Home page
 EuropaceHome page
F. G. Cosio, E. Aliot, G. L. Botto, H. Heidbuchel, C. J. Geller, P. Kirchhof, J.-C. De Haro, R. Frank, J. P. Villacastin, J. Vijgen, et al.
Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode
Europace, January 1, 2008; 10(1): 21 - 27.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
I. C. Van Gelder
Rhythm control for atrial fibrillation: Non-channel antiarrhythmic drugs are en vogue
Cardiovasc Res, April 1, 2007; 74(1): 8 - 10.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
Y. Yin
Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation: reply
Eur. Heart J., February 1, 2007; 28(3): 381 - 381.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
T. Liu and G. Li
Anti-inflammatory effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: potential benefits for the prevention of atrial fibrillation
Eur. Heart J., October 1, 2006; 27(19): 2370 - 2371.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.